What is Immutep Limited - ADR Annual Net Profit?

Immutep Limited - ADR Annual Net Profit fell 7.07% in the last year to $42.72 M. Its sector's average net profit growth for the last fiscal year was -32.44%.

What is Immutep Limited - ADR Stock Price?

Immutep Limited - ADR Stock Price fell 32.89% and underperformed its sector by 39.7% in the past year.

What is Immutep Limited - ADR Debt to Equity Ratio?

Immutep Limited - ADR Debt to Equity Ratio of 0.01 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

What is Immutep Limited - ADR Return on Equity(ROE)?

Immutep Limited - ADR Return on Equity(ROE) for the last financial year was -26.21%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is Immutep Limited - ADR Mutual Fund Holding?

Immutep Limited - ADR Mutual Fund Holding decreased by 0.07% in the last quarter to 1.18.

What is Immutep Limited - ADR Interest Coverage Ratio?

Immutep Limited - ADR Interest Coverage Ratio is -1395.24, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

What is Immutep Limited - ADR Institutional Holding?

Immutep Limited - ADR Institutional Holding decreased by 0% in the last quarter to 1.3.

How is the Immutep Limited - ADR today?

The Immutep Limited - ADR today is trading in the down by -1.95% at 1.51.

How has Immutep Limited - ADR performed historically?

The Immutep Limited - ADR is currently trading down -1.95% on an intraday basis in the past week the index rose 3.42%. The index has been down -21.76% in the past quarter and fell -32.89% in the past year. You can view this in the overview section.

Immutep Limited - ADR XNAS: IMMP

Immutep Limited - ADR Live Share Price Today, Share Analysis and Chart

Name: Immutep Limited - ADR: Is Infosys Ltd. worth buying?
Item: Immutep Limited - ADR
Rating: 0.89016675
Author: Trendlyne DVM scores

Download real time

1.51 -0.03 (-1.95%)

54.79% Fall from 52W High

32,255 XNAS Volume

XNAS 21 Apr, 2025 5:30 PM (EDT)

Immutep Limited - ADR Key Metrics

My Metrics

Select

Market Capitalization Below industry Median Unavailable in chosen country	219.8
Price to Book Below industry Median Unavailable in chosen country	3.2
Institutional holding current Qtr % Low in industry Unavailable in chosen country	1.3
Piotroski Score Below industry Median Unavailable in chosen country	2
Rel Perf vs Sector quarter% Unavailable in chosen country	-21.2
ROE Annual % Negative ROE Annual % Unavailable in chosen country	-26.2
RoA Annual % Negative RoA Annual % Unavailable in chosen country	-24.5

All financials are in AUD Million and price data in USD

Not Eligible

Expensive Valuation

5.2 / 100

Technically Bearish

30.4 / 100

No estimates available

Check Before You Buy

Check P/E Buy Sell Zone

Not enough data available

Immutep Limited - ADR Stock Price Analysis

Day Price Range -2.0% 1 Day return Unavailable in chosen country	1.5 (LTP) 1.51.6 LowHigh
Week Price Range 3.4% 1 Week return Unavailable in chosen country	1.5 (LTP) 1.41.6 LowHigh
Month Price Range -20.5% 1 Month return Unavailable in chosen country	1.5 (LTP) 1.31.9 LowHigh
52 Week Price Range -32.9% 1 Year return Unavailable in chosen country	1.5 (LTP) 1.33.3 LowHigh

View full Share Price History

Immutep Limited - ADR Live Price Chart

Switch to TradingView

Fetching data ...

Immutep Limited - ADR Stock Analysis

Immutep Limited - ADR stock analysis with key metrics, changes, and trends.

Immutep Limited - ADR Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Net Profit	$42.72 M	7.07%	negative	Annual Net Profit fell 7.07% in the last year to $42.72 M. Its sector's average net profit growth for the last fiscal year was -32.44%.
Stock Price	$1.51	-32.89%	negative	Stock Price fell 32.89% and underperformed its sector by 39.7% in the past year.
Debt to Equity Ratio	0.01	-	positive	Debt to Equity Ratio of 0.01 is less than 1 and healthy. This implies that its assets are financed mainly through equity.
Return on Equity(ROE)	-26.21 %	-26.21%	negative	Return on Equity(ROE) for the last financial year was -26.21%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.
Mutual Fund Holding	1.18 %	-0.07%	negative	Mutual Fund Holding decreased by 0.07% in the last quarter to 1.18.
Interest Coverage Ratio	-1395.24	-	negative	Interest Coverage Ratio is -1395.24, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).
Institutional Holding	1.30 %	0%	negative	Institutional Holding decreased by 0% in the last quarter to 1.3.

VIEW LESS

Loading data..

Immutep Limited - ADR - Company Profile

What does Immutep Limited - ADR do?

Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.

Immutep Limited - ADR Management structure

All Gross Remunerations are in AUD

Dr. Florian Vogl, M.D.,PhD

Chief Medical Officer

955.82 K

2024

Gross Remuneration

Year

Ms. Deanne Miller

Chief Operating Officer, General Counsel and Company Secretary

565.23 K

89.99 K

2024

Gross Remuneration

Year

Immutep Limited - ADR Live Share Price Today, Share Analysis and Chart

54.79% Fall from 52W High

Immutep Limited - ADR Key Metrics

Market Capitalization

Price to Book

Institutional holding current Qtr %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

Market Capitalization

Price to Book

Institutional holding current Qtr %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

Check Before You Buy

Check P/E Buy Sell Zone

Immutep Limited - ADR Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

Immutep Limited - ADR Live Price Chart

Immutep Limited - ADR Stock Analysis

Immutep Limited - ADR stock analysis with key metrics, changes, and trends.

Annual Net Profit fell 7.07% in the last year to $42.72 M. Its sector's average net profit growth for the last fiscal year was -32.44%.

Stock Price fell 32.89% and underperformed its sector by 39.7% in the past year.

Debt to Equity Ratio of 0.01 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE) for the last financial year was -26.21%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding decreased by 0.07% in the last quarter to 1.18.

Interest Coverage Ratio is -1395.24, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

Institutional Holding decreased by 0% in the last quarter to 1.3.

Immutep Limited - ADR - Company Profile

What does Immutep Limited - ADR do?

Immutep Limited - ADR Management structure

Dr. Florian Vogl, M.D.,PhD

Chief Medical Officer

Ms. Deanne Miller

Chief Operating Officer, General Counsel and Company Secretary

Mr. Marc Voigt

Director, Chief Executive Officer and Chief Financial Officer

Professor Dr. Frederic Triebel, M.D.

Executive Director and Chief Scientific Officer

Immutep Limited - ADR Board of directors

Mr. Marc Voigt

Director, Chief Executive Officer and Chief Financ

Professor Dr. Frederic Triebel, M.D.

Executive Director and Chief Scientific Officer

Dr. Russell J. Howard, PhD

Chairman of the Board

Ms. Lis Boyce

Independent Director

Mr. Pete A. Meyers

Deputy Chairman of the Board

Ms. Anne Anderson

Director

Immutep Limited - ADR FAQ

How is Immutep Limited - ADR today?

Immutep Limited - ADR today is trading in the red, and is down by -1.95% at 1.51.

How has Immutep Limited - ADR performed historically?

Immutep Limited - ADR is currently trading down -1.95% on an intraday basis. In the past week the stock rose 3.42%. stock has been down -21.76% in the past quarter and fell -32.89% in the past year. You can view this in the overview section.